...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Molecular cancer therapeutics >Bench to bedside and back again: personalizing treatment for patients with GIST.
【24h】

Bench to bedside and back again: personalizing treatment for patients with GIST.

机译：从床头到床再坐回去：对GIST患者进行个性化治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Gastrointestinal stromal tumor (GIST) is a great example of how science can affect outcomes in cancer patients. As a malignancy, GIST has fewer changes in its genome than do many other solid cancers. Thus, the discovery by Hirota and colleagues in 1998 that GIST contained mutations in c-KTT was a breakthrough for advancing the biology and treatment of GIST (1). Tyro-sine kinase inhibitors such as imatinib mesylate (also known as Gleevec; Novartis), an oral 2-phenylamino-pyrimidine derivative that acts as a selective inhibitor against several receptor tyrosine kinases, including KIT, platelet-derived growth factor receptor a (PDGFRA), and BCR-ABL, have significantly improved the outcomes for GIST patients, who previously faced a very poor prognosis.
机译：胃肠道间质瘤（GIST）是科学如何影响癌症患者预后的一个很好的例子。作为一种恶性肿瘤，GIST的基因组变化少于许多其他实体癌。因此，Hirota及其同事在1998年发现GIST在c-KTT中含有突变，这是推进GIST生物学和治疗的突破（1）。酪氨酸激酶抑制剂，例如甲磺酸伊马替尼（也称为Gleevec;诺华），一种口服2-苯基氨基-嘧啶衍生物，可选择性抑制几种受体酪氨酸激酶，包括KIT，血小板衍生的生长因子受体（PDGFRA ）和BCR-ABL显着改善了GIST患者的预后，这些患者以前的预后很差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号